phone Contact Us

Business Updates

Graduation of HKSTP Incu-Bio Programme

Graduation of HKSTP Incu-Bio Programme

Hong Kong, 28 December 2019

Opharmic Graduates from HKSTP Incu-Bio Programme

Opharmic Technology (HK) Limited is proud to announce its successful graduation from the Hong Kong Science and Technology Parks (HKSTP) Incu-Bio Programme.

This milestone represents a significant step in the company's development, transitioning from an incubated startup to an independent medtech innovator while continuing to leverage the vibrant HKSTP ecosystem as a tenant. The Incu-Bio Programme provided critical support, including access to state-of-the-art facilities, mentorship from industry experts, and networking opportunities that accelerated Opharmic's early R&D efforts.

Since its inception as a HKUST spin-off, Opharmic has focused on pioneering ultrasound technologies for non-invasive drug delivery. Participation in the programme enabled substantial progress on its core platform: MeticTouch® for retinal disease management, designed to replace horrifying eye injections through the novel targeted ultrasound system.

"We are grateful for the foundational support from HKSTP, which has been instrumental in validating our technology and refining our vision," said Dr. Langston Suen, CEO of Opharmic Technology. "Graduating from the Incu-Bio Programme positions us strongly to advance toward clinical milestones and strategic partnerships."

Looking ahead, Opharmic remains committed to its mission of developing patient-centric, non-invasive solutions that improve accessibility and outcomes in eye health and beyond. The company will continue to collaborate with the HKSTP community while scaling its operations and pipeline.

Author

Opharmic Technology